How strong is the evidence for stem-cell therapy in Lupus (SLE)?
ClinicalTrials.gov registrations alone cannot establish how strong the evidence is. Registry activity is active but still early, with limited late-phase registration: the registry holds 44 records, 13 completed, 4 at Phase 3 or 4, and 7 stopped early (16%). MSC-specific work accounts for 21 of those records. These counts describe research activity and maturity, not benefit, safety or certainty. Snapshot 2026-08-29.
What counts as a real result in Lupus (SLE)
Meaningful outcomes are validated disease-activity indices, steroid dose reduction and organ-specific measures such as proteinuria, sustained over a year. Lupus relapses and remits on its own, so timing an intervention near a flare almost guarantees an apparent response.
What we can say from registrations alone
- Volume: 44 registered studies since 2000.
- Maturity: 4 confirmatory-phase records.
- Delivery: 13 completed; 7 terminated, withdrawn or suspended.
- Scale: median planned enrolment 20 participants, largest 2,240.
The completed studies
Completed does not mean published, and published does not mean positive. These are the finished records — the starting point for checking whether results ever appeared.
| Study | Phase | Status | Planned n | Lead sponsor | Start |
|---|---|---|---|---|---|
| NCT04870333 — PROphylaxis for paTiEnts at Risk of COVID-19 infecTion -V | Phase 2, Phase 3 | Completed | 2,240 | Cambridge University Hospitals NHS Foundation Trust | 2021-02-19 |
| NCT02633163 — Phase 2 Trial of Mesenchymal Stem Cells in Systemic Lupus Erythematosus (MiSLE) | Phase 2 | Completed | 81 | Medical University of South Carolina | 2018-11-18 |
| NCT00271934 — Immune Ablation and Hematopoietic Stem Cell Support in Patients With Systemic Lupus Erythematosus: A Phase II Study | Phase 2 | Completed | 52 | Northwestern University | 2002-09 |
| NCT03979976 — Ramipril, Endothelial Function and Endothelial Progenitor Cells in Patients With Systemic Lupus Erythematosus | Phase 2, Phase 3 | Completed | 37 | Federal University of São Paulo | 2011-03 |
| NCT00278538 — Cyclophosphamide and Rabbit Antithymocyte Globulin (rATG)/Rituximab in Patients With Systemic Lupus Erythematosus | Phase 2 | Completed | 32 | Northwestern University | 2005-09-23 |
| NCT03828071 — Autologous Hematopoietic Stem Cell Transplantation for Refractory Lupus Nephritis | n/a | Completed | 22 | Nanjing University School of Medicine | 2011-06-01 |
What registrations cannot tell you
Whether results were positive. Whether they were published at all — a large share of registered studies never report outcomes, which biases what the literature appears to show. And whether the product a commercial clinic sells resembles the product studied: cell source, dose, processing and delivery route vary enormously between a registered protocol and an off-protocol injection.
How to use this when someone is selling you a treatment
Ask which specific registered study supports the offer, then compare its intervention description with your quote. If the answer is a general gesture at "Lupus (SLE) research", you are being sold the field's activity rather than evidence about the product. The Provider Question Builder turns that gap into questions.
Frequently asked
How strong is the evidence for stem-cell therapy in Lupus (SLE)?
ClinicalTrials.gov registrations alone cannot establish how strong the evidence is. Registry activity is active but still early, with limited late-phase registration: 44 registered records, 4 at Phase 3/4 and 7 stopped early (2026-08-29).
Has any stem-cell product been approved for this condition?
That has to be checked per product with the regulator that governs where you would be treated. A clinic's own claim of approval is not verification.
Why do clinics cite hundreds of studies?
Because counting registrations is easy and sounds authoritative. The number that matters is how many controlled studies reported a clinically meaningful outcome for the product being sold.
Registry and literature counts retrieved 2026-08-29 (ClinicalTrials.gov API v2; PubMed E-utilities). Registration or publication volume measures research activity, not effectiveness or approval. Educational information — not medical advice; verify product, indication, legal pathway and evidence with an independent qualified physician. Page generated 2026-08-29. See our editorial standards.